Aligos Reports Pevifoscorvir Sodium Data Suggesting HBV cccDNA Reduction

Event summary

  • 40% of HBeAg+ chronic HBV patients treated with pevifoscorvir sodium achieved HBsAg reductions qualifying them for functional cure therapy.
  • Phase 1 data suggests pevifoscorvir sodium may reduce cccDNA reservoir through secondary CAM-E mechanism.
  • Combination of pevifoscorvir sodium and ALG-170675 showed additive to synergistic effects in reducing HBV markers.
  • Preclinical data presented at EASL Congress 2026 highlights potential for pevifoscorvir sodium to replace nucleos(t)ide analogs as standard of care.

The big picture

Aligos' data suggests a potential paradigm shift in chronic HBV treatment, moving beyond viral suppression to functional cure. The focus on cccDNA reduction aligns with industry efforts to eliminate HBV infection rather than just manage it. If validated, this approach could position Aligos as a leader in next-generation HBV therapies. The strategic partnership with Amoytop for the ASO program further strengthens Aligos' position in the functional cure space.

What we're watching

Clinical Validation
Whether pevifoscorvir sodium can sustain its cccDNA reduction effects in larger, longer-term studies.
Combination Strategy
The pace at which Aligos advances pevifoscorvir sodium and ALG-170675 as a combined functional cure regimen.
Market Positioning
How pevifoscorvir sodium's potential to replace nucleos(t)ide analogs impacts Aligos' competitive standing.